Trimedyne, Inc.

by Robert Neil The convergence of innovative technologies capable of harnessing a variety of powerful energy sources along with patients and physicians actively seeking more effective and less-invasiv

GERD and Barrett's Esophagus seem like obvious—and enormous—potential markets for interventional devices, but so far such devices have disappointed. Companies with new approaches believe that now the

Laser companies hope to disassociate themselves from the pronouncement by cardiologist Martin Leon that direct myocardial revascularization is dead. by Mary Stuart Suffice it to say, cardiologist Mart

A new biological treatment for coronary artery disease looms on the horizon. Will cardiovascular devices help the biotechnology approaches deliver? by Mary Stuart In February, Genentech Inc. delive